MedTrace Logo

Establishment of MRI Model for pTRG in Rectal Cancer With Establishment of

NCT05374044 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 385

Last updated 2023-06-22

No results posted yet for this study

Summary

This study proposeto integrate a variety of imaging quantitative indicators to establish a new MRI-based tumor response regression(mrTRG) classification method. The accuracy of the established mrTRG classification method according pathology TRG(pTRG) will be tested. The ability of the established mrTRG classification method to predict prognosis will also be tested.

Conditions

Interventions

DIAGNOSTIC_TEST

pelvic MRI for establishing new mrTRG method

they will received two pelvic MR examinations before and after neoadjvant therapy. The MRI before neoadjvant therapy is considered as baseline MRI, which is usually taken within 3 weeks before NAT. The MRI after neoadjvant therapy is considered as preoperative MRI, which is usually taken within 3-8 weeks before NAT.

Sponsors & Collaborators

  • Capital's Funds for Health Improvement and Research (2020-1- 2151).

    collaborator UNKNOWN

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Ying-Shi Sun, MD · Peking University Cancer Hospital & Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-18
Primary Completion
2023-04-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05374044 on ClinicalTrials.gov